Journal
ADDICTIVE BEHAVIORS
Volume 38, Issue 9, Pages 2433-2436Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.addbeh.2013.03.011
Keywords
Nicotine; Smoking cessation; Addiction; Cannabidiol; Endocannabinoids
Categories
Funding
- Medical Research Council, UK
- MRC [G0800268, G0802718] Funding Source: UKRI
- Medical Research Council [G0802718, G0800268] Funding Source: researchfish
Ask authors/readers for more resources
The role of the endocannabinoid system in nicotine addiction is being increasingly acknowledged. We conducted a pilot, randomised double blind placebo controlled study set out to assess the impact of the ad-hoc use of cannabidiol (CBD) in smokers who wished to stop smoking. 24 smokers were randomised to receive an inhaler of CBD (n = 12) or placebo (n = 12) for one week, they were instructed to use the inhaler when they felt the urge to smoke. Over the treatment week, placebo treated smokers showed no differences in number of cigarettes smoked. In contrast, those treated with CBD significantly reduced the number of cigarettes smoked by similar to 40% during treatment. Results also indicated some maintenance of this effect at follow-up. These preliminary data, combined with the strong preclinical rationale for use of this compound, suggest CBD to be a potential treatment for nicotine addiction that warrants further exploration. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available